Data / Form D filings / Prolifagen, Inc.
Prolifagen, Inc.: Form D filing
Prolifagen, Inc., a biotechnology company in Doylestown, PA, filed a Form D with the SEC in 2025. The latest, on September 23, 2025, reports $3 million sold of an offering with no set size to 6 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 3805 OLD EASTON ROAD, SUITE 2242, Doylestown, PA, 18902
- Phone
- (610) 656-5229
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2025
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 2086999
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Sep 23, 2025 | New notice | Indefinite | $3,026,864 | 6 | Sep 2, 2025 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| M. Alexander Shaw | Director | |
| Andreas Alexander Bader | Executive Officer | |
| William Alexander Houston | Executive Officer | |
| Michael Behr | Executive Officer, Director | |
| Claudine Bruck | Executive Officer, Director |
Other biotechnology companies in Pennsylvania that filed recently
- BioLattice Ophthalmics, Inc, $1.8 million · Oct 28, 2026
- Myris Therapeutics, Inc. $500,000 · Oct 14, 2026
- Praeventix, Inc. $5.6 million · Sep 10, 2026
- Plowshare Therapies LLC $6.7 million · Aug 31, 2026
- Noveome Biotherapeutics, Inc. $6.8 million · Aug 27, 2026
- AlloTRx Bio Inc. $500,000 · Aug 24, 2026
Every Form D from the week of Sep 22, 2025 · All recent filings in Pennsylvania · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Prolifagen, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.